310 related articles for article (PubMed ID: 15592080)
1. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction.
Franco I; Horowitz M; Grady R; Adams RC; de Jong TP; Lindert K; Albrecht D
J Urol; 2005 Jan; 173(1):221-5. PubMed ID: 15592080
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
Cartwright PC; Coplen DE; Kogan BA; Volinn W; Finan E; Hoel G
J Urol; 2009 Oct; 182(4):1548-54. PubMed ID: 19683731
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Kennelly MJ; Lemack GE; Foote JE; Trop CS
Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
[TBL] [Abstract][Full Text] [Related]
4. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.
Madersbacher H; Mürtz G; Alloussi S; Domurath B; Henne T; Körner I; Niedeggen A; Nounla J; Pannek J; Schulte-Baukloh H; Schultz-Lampel D; Bock P; Strugala G
BJU Int; 2009 Mar; 103(6):776-81. PubMed ID: 19007380
[TBL] [Abstract][Full Text] [Related]
5. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
Stöhrer M; Mürtz G; Kramer G; Schnabel F; Arnold EP; Wyndaele JJ;
Eur Urol; 2007 Jan; 51(1):235-42. PubMed ID: 16698176
[TBL] [Abstract][Full Text] [Related]
6. Detrusor overactivity in spina bifida: how long does it need to be treated?
Ab E; Dik P; Klijn AJ; van Gool JD; de Jong TP
Neurourol Urodyn; 2004; 23(7):685-8. PubMed ID: 15382196
[TBL] [Abstract][Full Text] [Related]
7. Postpubertal urodynamic and upper urinary tract changes in children with conservatively treated myelomeningocele.
Almodhen F; Capolicchio JP; Jednak R; El Sherbiny M
J Urol; 2007 Oct; 178(4 Pt 1):1479-82. PubMed ID: 17706702
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
9. [The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization].
Yokoyama O; Ishiura Y; Nakamura Y; Ohkawa M
Hinyokika Kiyo; 1995 Jul; 41(7):521-4. PubMed ID: 7668182
[TBL] [Abstract][Full Text] [Related]
10. [Topical treatment with oxybutynin chloride in neurogenic incontinence].
López Pereira P; Martínez MJ; Muguerza R; Jaureguizar E
Cir Pediatr; 1993 Jan; 6(1):29-31. PubMed ID: 8499234
[TBL] [Abstract][Full Text] [Related]
11. Evidence of a peripheral role of neurokinins in detrusor hyperreflexia: a further study of selective tachykinin antagonists in chronic spinal injured rats.
Abdel-Gawad M; Dion SB; Elhilali MM
J Urol; 2001 May; 165(5):1739-44. PubMed ID: 11342967
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
[TBL] [Abstract][Full Text] [Related]
13. Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia.
Painter KA; Vates TS; Bukowski TP; Fleming P; Freedman AL; Smith CA; Gonzalez R; Perlmutter AD
J Urol; 1996 Oct; 156(4):1459-62. PubMed ID: 8808907
[TBL] [Abstract][Full Text] [Related]
14. Prospective open label study of solifenacin for overactive bladder in children.
Bolduc S; Moore K; Nadeau G; Lebel S; Lamontagne P; Hamel M
J Urol; 2010 Oct; 184(4 Suppl):1668-73. PubMed ID: 20728124
[TBL] [Abstract][Full Text] [Related]
15. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
Fader M; Glickman S; Haggar V; Barton R; Brooks R; Malone-Lee J
J Urol; 2007 Jan; 177(1):208-13; discussion 213. PubMed ID: 17162046
[TBL] [Abstract][Full Text] [Related]
16. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury.
O'Leary M; Erickson JR; Smith CP; McDermott C; Horton J; Chancellor MB
J Spinal Cord Med; 2003; 26(2):159-62. PubMed ID: 12828295
[TBL] [Abstract][Full Text] [Related]
17. [Clinical effects of oxybutynin hydrochloride in the treatment of unstable bladder and overactive neurogenic bladder: a long-term clinical trial].
Goto M; Kato K; Kondo A; Otani T; Takita T; Kobayashi M
Hinyokika Kiyo; 1988 Mar; 34(3):541-50. PubMed ID: 3389295
[TBL] [Abstract][Full Text] [Related]
18. Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele.
Kajbafzadeh AM; Moosavi S; Tajik P; Arshadi H; Payabvash S; Salmasi AH; Akbari HR; Nejat F
Urology; 2006 Nov; 68(5):1091-6; discussion 1096-7. PubMed ID: 17113899
[TBL] [Abstract][Full Text] [Related]
19. [Effects of long-term administration of oxybutynin hydrochloride (KL007) for the treatment of neurogenic bladder and unstable bladder].
Sonoda T; Sakurai T; Yamada K; Mizutani S; Tsujimoto Y; Ogawa T
Hinyokika Kiyo; 1989 Jan; 35(1):167-78. PubMed ID: 2658513
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity.
Reddy PP; Borgstein NG; Nijman RJ; Ellsworth PI
J Pediatr Urol; 2008 Dec; 4(6):428-33. PubMed ID: 19013412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]